Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Denosumab in Obese Subjects with Weight Loss and Bone Metabolism Risk Factors Following GLP-1 Receptor Agonist Therapy
KCT0011299Phase 2Not yet recruiting
- Sponsor
- Celltrion
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of denosumab in obesity, osteopenia and Metabolic osteopathies, sponsored by Celltrion. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
obesityosteopeniaMetabolic osteopathies
Beyond the preview
Go deeper on KCT0011299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011299.